Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin's Midcap Stock Picks with Huge Upside Potential
Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry. Ken Griffin tasted early success while trading during his college days, and it is safe to say that he has never looked back since. Despite huge setbacks during the financial crisis of 2008, he used his skills and determination to make a comeback where many others would have simply closed the fund and moved on.
The billionaire investor currently manages assets worth around $65 billion across his funds. Owing to its large size and track record of success, Ken Griffin's stock moves often make it to the news and are closely followed by investors. We decided to do the same, focusing on Mid-cap stocks that still had the potential to turn into established giants tomorrow.
To come up with the list of billionaire Ken Griffin's 10 midcap stock picks with huge upside potential, we looked at his latest 13F holdings and, among his significant holdings, only considered stocks between $10 billion and $40 billion in market cap. We then looked at the average analyst price target on Wall Street and ranked the stocks according to their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A healthcare professional discussing treatment options for a patient with a neurological disorder.
Stock Upside Potential: 45.88%
Citadel Investment Group's Stake: $346,451,879
Neurocrine Biosciences, Inc. operates as a developer, discoverer, and marketer of pharmaceuticals for neuroendocrine, neuropsychiatric, and neurological disorders. Its major product candidates include INGREZZA, Efmody capsules, Orilissa tablets, Oriahnn capsules, ALKINDI, and CRENESSITY.
The firm was upgraded by RBC Capital Markets from Sector Perform to Outperform, highlighting the recent market downturn as an attractive buying opportunity. However, the price target was adjusted by RBC analyst Brian Abrahams from $138 to $137, anticipating short-term fluctuations due to the latest quarter earnings and long-term uncertainty surrounding Medicare drug price talks.
RBC analysts think that the current share price is a good entry point for investors looking for a reliable biotech.
RBC Capital Markets' analyst Brian Abrahams stated:
Broader sector selloff and market downside has brought the stock to levels well below fundamental fair value, given an Ingrezza commercial franchise that we expect to be relatively solid and durable long term.
The company also reaffirmed its 2025 guidance after beating top-line estimates in the most recent quarter. Aided by ongoing direct-to-consumer initiatives and an expanded sales force, Neurocrine anticipates INGREZZA sales to reach $2.5 billion to $2.6 billion for the full year. Regardless of potential competition, this guidance demonstrates continued growth. Due to clinical adoption factors and delays in reimbursement processes, the company expects CRENESSITY's revenue to increase gradually. Moreover, Phase 3 trials for osavampator and NBI-568 are ongoing, with the firm setting aside $60 million to advance its product pipeline during 2025.
Overall, NBIX ranks 4th on our list of Billionaire Ken Griffin's midcap stock picks with huge upside potential. While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Goldman Sachs Has Mixed Feelings About CoreWeave (CRWV)—Here's Why
CoreWeave, Inc. (NASDAQ:) is one of the . On July 30, Goldman Sachs reiterated the stock as 'Neutral' and said that it is standing by its neutral rating ahead of earnings on Aug. 12. 'Since we launched coverage last April, CoreWeave's financial profile has largely played out (see our initiation report for more details), quieting some of the most draconian bear cases.' An experienced financial analyst working intently at their desk in a modern office setting. Goldman Sachs analyst Kash Rangan is both optimistic and cautious on CoreWeave. This is because while it has demonstrated impressive revenue growth, expanding its customer base and capacity, it is also not free from risks. Some of these risks are significant customer concentration, especially after a substantial deal with OpenAI, depreciation, and high debt levels. CoreWeave, Inc. (NASDAQ:CRWV) is a cloud platform provider that provides equipment for AI and other computing purposes. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Sign in to access your portfolio
Business Wire
4 minutes ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Business Wire
34 minutes ago
- Business Wire
Mogo Files Early Warning Report Following Partial Disposition of Shares of WonderFi Technologies
VANCOUVER, British Columbia--(BUSINESS WIRE)--This news release is issued by Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) ('Mogo' or the 'Company') pursuant to the early warning requirements of Canada's National Instrument 62-104 and National Instrument 62-103 with respect to common shares ('WonderFi Shares') of WonderFi Technologies Inc. (TSX: WNDR, OTCQB: WONDF) ('WonderFi'), a corporation with a head office at 371 Front Street West, Suite 304, Toronto, Ontario, M5V 3S8. On August 1, 2025, Mogo, through its wholly owned subsidiary Mogo Financial Inc. ('Mogo Financial'), disposed of 40,000,000 WonderFi Shares by way of private agreement (the 'Sale Transaction'). As a result of the Sale Transaction, Mogo's holdings in WonderFi decreased to less than 10% of the issued and outstanding WonderFi Shares. Immediately prior to the Sale Transaction, Mogo had beneficial ownership of, indirectly through Mogo Financial, and exercised control and direction over, 81,962,639 WonderFi Shares, representing approximately 12.39% of the issued and outstanding WonderFi Shares. Upon completion of the Sale Transaction, Mogo had beneficial ownership of, indirectly through Mogo Financial, and exercised control and direction over 41,962,639 WonderFi Shares, representing approximately 6.34% of the issued and outstanding WonderFi Shares. The WonderFi Shares disposed of under the Sale Transaction were sold for investment purposes. Mogo is holding the remaining WonderFi Shares for investment purposes and may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over WonderFi Shares or other securities of WonderFi through market transactions or private agreements. In the ordinary course of managing its investment in the WonderFi Shares, Mogo may continue to engage with the board and management of WonderFi from time to time on various matters, including but not limited to WonderFi's business, strategy, board and management. An early warning report (the 'Report') of Mogo will be filed on WonderFi's SEDAR+ profile at and can be obtained from Mogo at its head office 516-409 Granville St, Vancouver, BC, V6C 1T2, attention: Christy Cameron, or phone: 604.659.4380. About Mogo Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) is on a mission to build the future of intelligent finance, empowering consumers to grow wealth through a suite of innovative financial products and a capital strategy anchored by Bitcoin. The company's platform combines digital wealth management and lending with a growing commitment to hard asset capital allocation. Mogo is publicly listed on the NASDAQ and TSX. Forward-Looking Statements This news release may contain 'forward-looking statements' within the meaning of applicable securities legislation, including statements regarding the filing of the Report and the disposition or acquisition of additional WonderFi Shares or other securities of WonderFi by Mogo. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at the time of preparation, are inherently subject to significant business, economic and competitive uncertainties and contingencies, and may prove to be incorrect. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Mogo's growth, its ability to expand into new products and markets and its expectations for its future financial performance are subject to a number of conditions, many of which are outside of Mogo's control. For a description of the risks associated with Mogo's business please refer to the 'Risk Factors' section of Mogo's current annual information form, which is available at and Except as required by law, Mogo disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise.
